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Leishmania braziliensis is the most prevalent species isolated from patients displaying cuta-
neous and muco-cutaneous leishmaniasis in South America. However, there are difficulties
for studying L. braziliensis pathogenesis or response to chemotherapy in vivo due to the nat-
ural resistance of most mouse strains to infection with these parasites. The aim of this work
was to develop an experimental set up that could be used to assess drug efficacy against L.
braziliensis. The model was tested using miltefosine.
Methodology/Principal Findings
A L. braziliensis line, originally isolated from a cutaneous leishmaniasis patient, was pas-
saged repeatedly in laboratory rodents and further genetically manipulated to express lucif-
erase. Once collected from a culture of parasites freshly transformed from amastigotes, 106
wild type or luciferase-expressing stationary phase promastigotes were inoculated subcuta-
neously in young BALB/c mice or golden hamsters. In both groups, sustained cutaneous
lesions developed at the site of inoculation, no spontaneous self- healing being observed 4
months post-inoculation, if left untreated. Compared to the wild type line features, no differ-
ence was noted for the luciferase-transgenic line. Infected animals were treated with 5 or 15
mg/kg/day miltefosine orally for 15 days. At the end of treatment, lesions had regressed and
parasites were not detected. However, relapses were observed in animals treated with both
doses of miltefosine.
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Conclusions/Significance
Here we described experimental settings for a late-healing model of cutaneous leishmania-
sis upon inoculation of a luciferase-expressing L. braziliensis line that can be applied to drug
development projects. These settings allowed the monitoring of the transient efficacy of a
short-term miltefosine administration.
Author Summary
Leishmania braziliensis is the most prevalent species isolated from patients displaying
either cutaneous or mucocutaneous leishmaniasis in South America. In this study, we
developed a transgenic luciferase-expressing L. braziliensis line. These parasites were pas-
saged in hamsters and mice and then transformed back into promastigotes. Once inocu-
lated subcutaneously in the footpad of young laboratory animals—BALB/c mice or golden
hamsters, rapid and sustained footpad thickness increase developed. This experimental
model was used to monitor the parasite load fluctuations and the response to miltefosine
treatment. Mice were treated orally over a two-week period, starting at week 4 post-inocu-
lation. Though such a regimen was shown to display efficacy, the effect was not sustained
and both parasite re-expansion and delayed footpad thickness increase were noticed.
Introduction
Leishmania spp. are the etiological agents of leishmaniasis, a complex of vector-borne infec-
tious diseases transmitted by sand flies. The disease is widespread in the world in tropical and
subtropical regions. Approximately 12 million people are affected worldwide and 1.2 million
new cases occur each year [1]. Leishmaniasis is responsible for a spectrum of clinical manifesta-
tions including visceral, cutaneous, mucosal, disseminated and diffuse cutaneous disease that
are determined, at least partially, by the species of the parasite [2]. In South America, Leish-
mania (Viannia) braziliensis is the most prevalent species isolated from patients displaying
either cutaneous or mucocutaneous leishmaniasis [3–5]. This species is also associated with
disseminated leishmaniasis [5].
In spite of its epidemiological importance, the study of L. braziliensis infections is limited by
the difficulty of establishing good animal models of disease. L. braziliensis infects hamsters and
induces a chronic cutaneous disease with no spontaneous healing [6, 7]. However, inbred
strains of mice are generally resistant to L. braziliensis or develop a transient and self-healing
cutaneous lesion [7–10]. When the parasites are inoculated into partially susceptible strains
such as BALB/c mice, a non-ulcerative lesion develops initially and evolves to spontaneous
healing in about 30 days [8, 10]. A mouse model of sustained skin lesions with L. braziliensis
would be very useful for studies on the pathogenesis of the disease as well as a tool to develop
new control strategies, such as vaccines and drugs.
The treatment of leishmaniasis relies on a few drugs, most of them displaying some inade-
quacy to present requirements. They are expensive, toxic and require prolonged and parenteral
administration. Additionally, drug resistance has been reported [11, 12]. More than a decade
ago, miltefosine (MF) was described as an oral drug against visceral leishmaniasis (VL) and has
been widely used in the Indian subcontinent for that application [13–15]. On the other hand,
MF efficacy for the treatment of cutaneous leishmaniasis (CL) seems to be dependent on the
Leishmania species and even on intraspecies heterogeneity. Some clinical studies in South
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America identified cure rates varying from 53% to 91% in CL patients [16–18]. Two clinical
studies performed in Brazil detected cure rates of 71.4% and 75%, respectively, in infections
due to L. guyanensis [19] and L. braziliensis [20]. However, given the lack of other new treat-
ment alternatives, further understanding of MF’s potentialities and limitations is necessary.
We have recently described the use of luciferase as a reporter for drug efficacy evaluation in
cutaneous and visceral leishmaniasis models [21, 22]. In both models, luciferase has proven to
be an accurate measure of parasite burden.
In this study, we generated a transgenic line of L. braziliensis expressing luciferase that was
adapted to induce chronic lesions in BALB/c mice. Using this experimental model, we evalu-
ated the efficacy of MF to reduce lesion size and parasite load.
Methods
Drugs
Amphotericin B sodium deoxycholate and MF were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Stock solutions of amphotericin B and MF for in vitro experiments were prepared
in sterile water (10 mM). Miltefosine used for the treatment of infected mice was prepared
daily in sterile saline (0.9% NaCl) from a 6 mg/mL stock solution.
Parasites
The L. braziliensis strain MHOM/BR/94/H3227 was kindly provided by Dr. Maria Jania Teix-
eira, from Universidade Federal do Ceará. These parasites were isolated from a cutaneous ulcer
from a patient in Ceará State, Brazil and the strain was previously typed as L. braziliensis [10].
Promastigotes were grown in mediumM199 (Sigma-Aldrich) supplemented with 10% heat-
inactivated foetal calf serum, 2% urine, 0.25% hemin, 12 mMNaHCO3, 50 U/mL penicillin
and 50 μg/mL streptomycin at 25°C. For in vivo experiments, female BALB/c mice (4–5 week-
old) were inoculated with 106 stationary-phase promastigotes injected subcutaneously in
the right hind footpad. Amastigotes were obtained from infected mice, as described [23] and
differentiated back as promastigotes in M199. Promastigotes were counted in a Neubauer
haemocytometer.
Generation of a transgenic line of L. braziliensis expressing luciferase
A construct containing the luc2 gene was previously built [22] taking advantage of the vectors
pSSU-int and pSPαHYGα which were kindly provided by Dr. Tony Aebischer (Robert Koch
Institute, Berlin, Germany) and Dr. Marc Ouellette (Universite Laval, Quebec, Canada). The
linear cassette purified upon Pac I and Pme I digestion of the construct described previously,
was used to transfect L. braziliensis H3227 promastigotes. Briefly, the cassette contains the
luc2 gene followed by a Leishmania 3’ UTR, the hygromycin phosphotransferase gene and
fragments of the L.mexicana small subunit (SSU) ribosomal DNA (rDNA) at the cassette
extremities to promote homologous recombination. Transfection was performed as described
[24] using 5 μg of linear DNA. Twenty-four hours after transfection, 32 μg/mL hygromycin B
was added for selection of mutants. The L. braziliensis transfectant line was kept for three pas-
sages in M199 containing hygromycin B and then plated on semi-solid M199 medium/1%
agar supplemented with 1.2 μg/mL biopterin, 2% urine and 32 μg/mL hygromycin B for clon-
ing [24]. Four independent clones were analysed for integration of the cassette into the rDNA
locus by PCR amplification, using primers complementary to sequences inside and outside
of the linear cassette. Genomic DNA of these clones was purified as described [25] for confir-
mation by PCR. Primers used were S1 (5’-GATCTGGTTGATTCTGCCAG-3’) and S4
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(5’-GATCCAGCTGCAGGTTCACC-3’) [26] that anneal to the SSU rDNA sequence flanking
the insertion sites and primers luc2F (5’-GCGGGATCCATGGAAGATGCCAAAAACAT
TAAG-3’), luc2R (5’-CACGCGCATACATTCACGGCGTTACACGGCGATCTTGCCGC-
3’) and luc2i (5’-GACCGACTACCAGGGCTTCC-3’) that anneal to the luc2 gene contained
in the linear cassette (Fig 1A) [22].
Parasite susceptibility to drugs in vitro
Susceptibility of L. braziliensis wild type and transgenic lines to amphotericin B and MF was
evaluated by a [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT, Sigma-
Aldrich) viability test assay as described [27]. For this assay, promastigotes (2×106 parasites per
well) were incubated in the presence of increasing concentrations of amphotericin B (0.037 to
0.3 μM) or MF (25 to 200 μM) for 24 h. MTT cleavage was measured in a microplate reader
(POLARstar Omega, BMG Labtech, Ortenberg, Germany) with a test wavelength of 595 nm
and a reference wavelength of 690 nm.
For intracellular amastigotes, bone marrow-derived macrophages (BMDM) from BALB/c
mice were used as previously described [21]. BMDM were plated on round glass coverslips in
24-well culture dishes, at a density of 3 × 105 cells in 400 μL of RPMI 1640 medium (Gibco,
Invitrogen Corporation) supplemented with 10% FCS (Gibco, Invitrogen Corporation) in a 5%
CO2 atmosphere for 16 h at 37°C allowing macrophages to adhere. Macrophages were then
infected with stationary-phase promastigotes using ratios varying from 20 to 35 parasites
per macrophage for 3 h at 33°C. Non-internalized parasites were removed by washing with
warmed PBS, followed by the addition of fresh medium containing increasing concentrations
of amphotericin B (0.025 to 0.2 μM) or MF (0.5 to 24 μM). After 48 h, the cells were fixed in
methanol and stained using the panoptic haematological labelling method (Instant Prov kit,
Newprov, Pinhais, PR, Brazil). The percentage of infected macrophages was determined by
counting 100 cells in three independent experiments. The half-maximal effective concentra-
tions (EC50) were determined from sigmoidal regression of the concentration-response curves.
Assays were performed in triplicate and results are expressed as the mean and standard devia-
tion (SD) of at least three independent experiments.
Luciferase assay in vitro
The activity of luciferase was measured in recombinant L. braziliensis promastigotes at loga-
rithmic and stationary growth phases. Parasites were washed twice with PBS and then serially
diluted for the luciferase assay, which was performed using the One Glo Luciferase Assay Sys-
tem (Promega Corporation) according to the manufacturer’s instructions and as described
previously [22]. Bioluminescence was measured in a microplate reader (POLARstar Omega,
BMG Labtech, Ortenberg, Germany). Each point was tested in triplicate in two independent
experiments.
Animal infections
Male golden hamsters (3 to 5 weeks-old) were obtained from the Instituto de Medicina Tropi-
cal, University of São Paulo. Female BALB/c mice (3 to 5 weeks-old) were from the Instituto de
Ciências Biomédicas, University of São Paulo. Animals were kept in cages and received unlim-
ited food and water.
Given that the wild type (Lb-WT) and luciferase transgenic parasites (Lb-LUC) were in dif-
ferent passages as promastigote cultures, they were initially used to inoculate highly susceptible
hamsters. Initially, 106 stationary phase promastigotes were injected into hamsters’ hind foot-
pads in a volume of 30 μL. Once the infections were established, parasites of both lines were
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recovered from the inoculated footpads and differentiated back into promastigotes in M199 at
25°C. These promastigotes were then used to inoculate BALB/c mice using the same protocol
described above, except for the host. When the lesions developed, parasites were recovered,
transformed into promastigotes and used to inoculate mice and hamsters with the results
described in the Results section. Disease progression was followed for 11 weeks in hamsters
and for 24 weeks in BALB/c mice.
Treatment of mice with MF and evaluation of treatment efficacy
BALB/c mice inoculated with Lb-WT or Lb-LUC were submitted to treatment with MF. Treat-
ment was initiated 4 weeks post-inoculation, using two different doses of the drug: 5 or 15 mg/
kg/day, in groups of 5 animals. MF was prepared daily from a stock solution of 6 mg/mL and
was administered by oral gavage for 15 consecutive days. An untreated group was used as a
control for each line studied. Lesion sizes were evaluated once a week by measuring the differ-
ence in thickness between the infected and the contralateral uninfected footpad using a caliper
(Mitutoyo Corporation, Kawasaki, Kanagawa, Japan).
Fig 1. Characterisation of a transgenic line of L. braziliensis expressing luciferase. (A) Schematic representation of the linear cassette for integration in
the SSU rDNA locus. SSU, small subunit; SAS, splice acceptor site; luc2, luc2 coding sequence; α-tub IR, intergenic region of the L. enrietii α-tubulin gene;
hyg, hygromycin phosphotransferase gene; CPB IR, L.mexicana cysteine protease B gene intergenic region. Position of the primers and size of amplified
fragments are indicated by the dotted lines. (B) Size separation of PCR products amplified using primers complementary to the luc2ORF extremities from
genomic DNA purified from four independent transfected clones (lanes 1 to 4) and from the wild type strain (lane 5). (C) Agarose gel electrophoresis of
amplified products obtained from Lb-WT (lane 1) or Lb-LUC (lane 2) with the pairs of primers S1/luc2R or luc2i/S4. (-) indicates the control reaction without
template DNA. (D) Luminescence intensity and number of Lb-LUC promastigotes. Promastigotes were serially diluted and luminescence was measured
using a microplate reader, after addition of luciferin. RLU, relative light units.
doi:10.1371/journal.pntd.0004660.g001
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Parasite burden in Lb-LUC inoculated BALB/c mice was determined 6 weeks (at the end of
MF treatment), 17 and 23 weeks post-inoculation. The parasite load was quantified by measur-
ing luciferase activity through bioimaging (IVIS Spectrum, Caliper Life Sciences, Inc. MA/
USA) as described [21]. Briefly, before luminescence detection animals received 75 mg/kg lucif-
erin (VivoGlo Luciferin, Promega) intraperitoneally followed by anesthesia in a 2% isoflurane
atmosphere (Cristália). Images were collected after 20 minutes using a high-resolution mode
with 2 minutes exposure from a fixed-size region of interest. Results were quantified with Liv-
ing Image software version 4.3.1 (Caliper Life Sciences) and were expressed as photons/sec-
ond/square centimeter/steradian (ph/sec/cm2/sr).
Susceptibility to MF after in vivo treatment
Lb-WT parasites were recovered from infected mice that had been treated with 5 mg/kg/day
(n = 5) or with 15 mg/kg/day (n = 5) MF at the 19th and 23th week post-inoculation, respec-
tively. These parasites were differentiated into promastigotes in M199 medium and their sus-
ceptibility to MF was determined by the MTT assay as described above. As controls, parasites
were also rescued from an untreated infected animal at the 19th week post-infection.
Statistical analysis
Unpaired two-tailed Student’s t tests were used to compare the EC50 determined in vitro on
promastigotes and intracellular amastigotes of wild type parasites and luciferase expressing
lines and for comparing disease progression. Parasite burden was analysed for statistical signifi-
cance by One Way ANOVA, followed by the Tukey post-test. All statistical analyses were per-
formed using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA USA).
Results were considered significant at P< 0.05.
Ethics statement
Animal experiments were approved by the Ethics Committee for Animal Experimentation of
the Biomedical Sciences Institute (Protocol: 178/138/02) and of the Tropical Medicine Institute
(Protocol: CPE-IMT 2012/145) of the University of São Paulo in agreement with the guidelines
of the Sociedade Brasileira de Ciência de Animais de Laboratório (SBCAL) and of the Conselho
Nacional de Controle da Experimentação Animal (CONCEA).
Results
Generation and characterisation of a luciferase expressing line of L.
braziliensis
To generate a luciferase expressing L. braziliensis line (Lb-LUC), promastigotes of the H3227
strain were transfected with a linear cassette containing the luc2 gene flanked by SSU rDNA
sequences (Fig 1A). After transfection, parasites were selected in the presence of hygromycin B
and cloned. Four independent clones were tested for the presence of the luc2 gene by PCR.
Amplification of a 1.6 kb fragment with oligonucleotides complementary to the 5’ and 3’ ends
of the luc2 open reading frame was observed in the four selected clones while the same reaction
led to the absence of amplification from wild type parasites (Fig 1B). Additional pairs of prim-
ers were used to confirm the correct integration into the ribosomal DNA locus in one of the
selected clones (clone 3, lane 3 in Fig 1B). Primers S1 and S4 [26], complementary to the rDNA
outside the linear cassette, were used in combination with primers luc2R and luc2i, respectively
(Fig 1A). These two combinations of primers amplified the expected fragments of 2.4 and 6.7
kb in the transgenic line but not in wild type parasites (Fig 1A and 1C).
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Bioluminescence in the transgenic line (Lb-LUC) was confirmed after incubation of para-
sites with luciferin. A linear correlation between the number of promastigotes and the produc-
tion of light was observed (Fig 1D).
Growth curves for transgenic Lb-LUC and wild type (Lb-WT) promastigotes were indistin-
guishable (S1A Fig). Logarithmic and stationary phase promastigotes presented similar light
emission (S1B Fig) indicating that luciferase expression was stable along the growth curve. The
stability of the transgene was also evaluated by removing the drug pressure from promastigote
cultures. Luciferase expression was stable with the same levels of light production in parasites
kept in the absence of hygromycin B for 25 passages in culture (S1C Fig).
No differences were observed in the infectivity of Lb-LUC and Lb-WT to macrophages after
24 or 48 hours evaluated by the morphology of infected cells, percentage of infected cells or
number of amastigotes per infected macrophage (S2A–S2D Fig). In addition, a direct correla-
tion was observed between the number of Lb-LUC intracellular amastigotes per macrophage
and bioluminescence (S2E Fig). Finally, in vitro susceptibility of Lb-LUC and Lb-WT promasti-
gotes and intracellular amastigotes to amphotericin B and MF showed no significant differ-
ences (Table 1).
Disease progression in hamsters and BALB/c mice inoculated with Lb-
LUC
Hamsters and BALB/c mice were inoculated with 106 Lb-WT or Lb-LUC promastigotes subcu-
taneously in the footpad. In both animal models, there were no significant differences in the
kinetics of lesion development or in lesion size when the two parasite lines were compared (Fig
2A and 2B). In both models, lesions were non-ulcerative (Fig 2C and 2D). In hamsters, lesions
were detectable from two weeks post-inoculation, progressed steadily for the next five weeks
and then the oedema stabilized till the 11th week post-inoculation (Fig 2A), when animals were
euthanized. In BALB/c mice, lesions were clearly detected after two weeks, progressed in size
until weeks 9–10 and then decreased in the following weeks (Fig 2B and S3 Fig), but the local
oedema remained detectable until 23 weeks post-inoculation (Fig 2B and S3 Fig). Therefore, no
spontaneous healing was observed in the animal models studied during the period evaluated.
BALB/c mice inoculated with Lb-LUC were examined by in vivo imaging after 6, 17 and 23
weeks (Figs 3 and 4). Luminescence was detected from the lesion site in all mice at the 6th week
post-inoculation (Figs 3B and 4). By week 17th, light emission was not detected in 2 out of 5
mice (Figs 3C and 4). No bioluminescence was detected in untreated animals at the 23th week
post-inoculation (Figs 3D and 4), although measurable oedema was still observed in this group
at the 24th week (Fig 3A).
In vivo efficacy of MF in Lb-LUC inoculated BALB/c mice
The late-healing infection model of L. braziliensis H3227 in BALB/c mice was used to test MF
efficacy. Treatment was initiated 4 weeks post-inoculation in animals injected with the trans-
genic line Lb-LUC (Fig 3) or with the wild type parasites (S3 Fig). Animals were treated with
MF 5 or 15 mg/kg/day for 15 consecutive days. Both doses of MF resulted in regression of
lesions at the end of the treatment (6 weeks post-inoculation) (Fig 3A and S4 Fig). Lumines-
cence was not detected by bioimaging at the end of the treatment (Figs 3B and 4).
However, 8 weeks post-inoculation a relapse was observed in animals treated with 5 mg/kg/
day MF, with lesions progressing in size for the following weeks (Fig 3A and S3 Fig). These
findings were confirmed by quantification of bioluminescence 120 days post-inoculation (17th
week), time when animals treated with 5 mg/kg/day presented a higher parasite burden than
untreated animals (Figs 3C and 4).
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Table 1. Drug susceptibility in promastigotes and intracellular amastigotes of the wild type and the transgenic line of L. braziliensis H3227.
Drug EC50 ± S.D.
a
Promastigotes Intracellular amastigotes
Lb-WT Lb-LUC Lb-WT Lb-LUC
amphotericin B 0.11 ± 0.01 0.11 ± 0.02 0.05 ± 0.02 0.05 ± 0.01
miltefosine 40.70 ± 8.55 47.71 ± 5.85 0.99 ± 0.05 0.91 ± 0.01
a Half maximal effective concentration ± standard deviation (in μM). Results are the average of at least three independent experiments.
doi:10.1371/journal.pntd.0004660.t001
Fig 2. Course of disease after L. braziliensisH3227 inoculation in hamsters and BALB/c mice. Evolution of lesion size in hamsters (A) and BALB/c
mice (B) inoculated with Lb-LUC or Lb-WT H3227 strain. Animals were inoculated with 106 stationary-phase promastigotes in the left hind footpad and lesion
size was measured weekly (five animals per group). Data is the mean and standard deviation from one experiment representative of two independent
experiments. Student’s t test comparing the area under the curve detected non-statistically significant differences with P = 0.25 (A) and P = 0.11 (B).
Representative images of a hamster at the 5th week (C) and of a BALB/c mouse at the 6th week post-inoculation (D) with H3227 Lb-LUC parasites. The left
footpad (inoculated) and right footpad (control) of a hamster (C) and a BALB/c mouse (D), representative of each group of animals, are shown.
doi:10.1371/journal.pntd.0004660.g002
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Fig 3. In vivo efficacy of miltefosine in a L. braziliensis-inoculated BALB/c mice model. 106 Lb-LUC
stationary promastigotes were injected in the left hind footpad and animals were treated with 5 or 15 mg/kg/
day of miltefosine for 15 consecutive days (from to 4th to the 6th week post-inoculation). Average lesion size
was measured weekly (five animals per group) in untreated and treated animals and horizontal black bar
indicates MF treatment (A). Parasite burden was evaluated by bioluminescence at the end of the treatment
Leishmania braziliensis Leading to Sustained Skin Lesions in BALB/c Mice
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004660 May 4, 2016 9 / 16
A clinically detectable relapse was also observed in animals treated with 15 mg/kg/day from
the 15th week post-inoculation that progressed in the following weeks (Fig 3A). Although no
luminescence was detected in these animals at week 17th (120 days) post-inoculation (Figs 3C
and 4), parasites were clearly detected by in vivo imaging at the 23th week post-inoculation
(Figs 3D and 4).
Animals inoculated with Lb-WT and treated with both doses of MF presented the same pat-
tern of disease progression, response and relapse to treatment observed with the Lb-LUC trans-
genic line (Fig 3A and S3 Fig).
To investigate whether these relapses were due to MF resistance acquired during the therapy
regimen, parasites were recovered from 5 animals treated with MF 5 mg/kg/day (at the 19th
week post-inoculation) and with 15 mg/kg/day (at the 23th week post-inoculation) (S3 Fig).
After differentiation to promastigotes, MF susceptibility was determined in parasites isolated
from untreated and treated animals and no significant changes in drug susceptibility were
found between these parasites (Table 2).
Discussion
To the best of our knowledge, this is the first report of a luciferase-expressing L. braziliensis,
the causative species of cutaneous and mucocutaneous leishmaniasis in humans and the most
prevalent species in South America [2]. The importance of research on L. braziliensis infections
cannot be overstated. However, it faces multiple difficulties largely derived from the distinct
(6th week post-inoculation) (B), at the 17th (C) and at the 23th week post-inoculation (D) (40, 120 and 160 days
post-inoculation respectively). Statistical analysis was performed with OneWay ANOVA, followed by the
Tukey post-test. * p < 0.05; **, p < 0.001. Ph/sec/cm2/sr, photons per second per square centimetre per
steradian.
doi:10.1371/journal.pntd.0004660.g003
Fig 4. Parasite burden of left hind footpad of BALB/c mice treated with MF and evaluated by bioluminescence.Groups of 5 animals untreated (NT), or
treated with 5 or 15 mg/kg/day MF (MF 5 and MF 15 respectively) were evaluated at 40, 120 and 160 days (6th, 17th and 23th week respectively) post-
inoculation (pi). The bars on the right show a pseudo-colour scale representing light intensities.
doi:10.1371/journal.pntd.0004660.g004
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behaviour of this Leishmania species, in vitro and in vivo. L. braziliensis promastigotes do not
grow easily in axenic cultures and amastigotes are scarce in the lesions. The lack of an appro-
priate animal model mimicking the human infection in all of its potential clinical presentations
is perhaps one of the main drawbacks. Most L. braziliensis strains are infective to mice but lead
to asymptomatic or short-lived, self-healing disease [28, 29]. The infection is more sustained in
hamsters [6, 29], but do not progress to a mucosal or disseminated disease.
The development of lesions at the site of inoculation with the H3227 strain of L. braziliensis
in BALB/c mice was previously described [10]. However, in the original description, lesions
were self-limited and healed 30 days post-inoculation. This strain was kindly given to us by Dr.
Maria Jania Teixeira (Universidade Federal do Ceará, Brazil) and, before being submitted to
transfection, was passaged in mice repeatedly. Most likely as a result of these repeated in vivo
passages, the line obtained after transfection, together with the parental wild type parasites
were then able to induce a late-healing disease in BALB/c mice, as well as being pathogenic in
hamsters. A late-healing animal model of L. braziliensis infection is likely to become very useful
as a tool in drug development or in the evaluation of the disease pathogenesis.
It is unclear at present whether other strains of L. braziliensis could be adapted to cause late-
healing disease in BALB/c mice. We have attempted to do so with three other isolates as well as
with the type strain of L. braziliensisM2903 without success but cannot rule out that possibil-
ity. It will be interesting to investigate whether mutations on this Leishmania isolate (H3227)
are present and could be correlated with the altered phenotype.
These parasites were transformed to express the luciferase gene integrated into the ribo-
somal locus. Luciferase expression was stable throughout the life cycle. As previously reported
for other luciferase-expressing Leishmania species [21, 22, 30], this L. braziliensis transgenic
line presented the same biological properties in vitro and in vivo of the parental line and was
useful for parasite quantification of promastigotes and amastigotes, in vitro and in vivo. Lucif-
erase as a reporter has become instrumental in pre-clinical drug development projects, espe-
cially in chronic infections. Our previous results with L. amazonensis [21] and L. chagasi [22]
Table 2. Susceptibility of promastigotes to MF after recovery from BALB/c mice treated with 5 or 15
mg/kg/day.
Treatment regimen Lb-WT lines a EC50 ± S.D. b
Untreated Lb-WT (NT.1) 40.88 ± 6.77
5 mg/kg/day Lb-WT (MF5.1) 36.82 ± 6.10
Lb-WT (MF5.2) 34.33 ± 8.33
Lb-WT (MF5.3) 38.12 ± 9.75
Lb-WT (MF5.4) 41.45 ± 3.80
Lb-WT (MF5.5) 43.26 ± 9.05
15 mg/kg/day Lb-WT (MF15.1) 28.24 ± 2.31
Lb-WT (MF15.2) 28.20 ± 4.46
Lb-WT (MF15.3) 30.80 ± 4.76
Lb-WT (MF15.4) 29.00 ± 9.78
Lb-WT (MF15.5) 36.34 ± 8.68
a Amastigotes were rescued from Lb-WT inoculated BALB/c mice treated with MF 5 mg/kg/day (5 animals),
15 mg/kg/day (5 animals) or untreated (one animal) (MF5, MF15 and NT.1 respectively), differentiated in
M199 to promastigotes and then tested for MF susceptibility by MTT as described in Methods.
b Half maximal effective concentration ± standard deviation (in μM). Results are the average of at least
three independent experiments.
doi:10.1371/journal.pntd.0004660.t002
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lines expressing luciferase clearly demonstrated that luciferase detection correlates well with
parasite burden in vivo. In the case of H3227 parasites, the sensitivity of detection in vivo has
proven to be insufficient to detect low parasite burdens, as was the case in Lb-LUC in untreated
animals or when relapses were noticed in the groups treated with the higher dose of MF. This
limitation in sensitivity should be taken into account in drug efficacy studies. Nevertheless,
bioimaging was used successfully to document infection and as a semi-quantitative method for
comparing parasite burden between different groups.
The model of infection with Lb-LUC in BALB/c mice was put to test using MF, the newest
addition to leishmaniasis chemotherapy. The susceptibility of the H3227 strain to MF in vitro
can be considered comparable to other L. braziliensis strains [31, 32]. Accordingly, at the end
of MF treatment, Lb-LUC inoculated mice showed regression of lesions and absence of lumi-
nescence. However, although the doses used here were higher than the WHO recommended
scheme for CL and VL (2.5 mg/kg/day) [15], a clinical relapse was evident in animals treated
with 5 mg/kg/day as soon as two weeks after the end of treatment. In these animals, lesions
progressed in the following weeks reaching sizes similar to the ones observed in untreated ani-
mals. In animals treated with 15 mg/kg/day, oedema in the footpad reappeared 10 weeks after
the interruption of treatment.
Relapses in VL patients treated with MF do not seem to be due to acquired resistance [33].
Likewise, our data showed similar MF susceptibility in parasites rescued from untreated
and treated animals, indicating that L. braziliensis did not acquire resistance to MF during
treatment.
In VL patients, MF failure may be correlated with low drug exposure due to pharmacoki-
netic-pharmacodynamics factors [34]. MF has been shown to reach high levels in the skin [15]
but poor drug distribution to cutaneous lesions may be another reason for the lower efficacy of
the drug against CL when compared with VL. Furthermore, the greater genetic diversity of L.
braziliensis compared to L. donovani [35, 36] may increase the number of elements that con-
tribute to treatment failure. Moreover, other factors, unrelated to drug resistance, should be
considered as quiescence and even the presence of the LRV1 virus [37, 38].
The persistence of viable parasites after treatment with 5 and 15 mg/kg/day MF per 15 days
indicated that, even for the highest dose used, clinical response did not reflect sterile cure. In
fact, sterile cure does not seem to be required for long-term control of the disease, as has been
shown by the presence of parasites in healthy skin in animals [39, 40]. On the other hand,
relapses have been reported in patients treated with MF for all clinical forms of the disease [33,
41–46]. Therefore, we believe the data presented herein stress the need for long-term follow up
of MF treated patients and suggest that higher doses and/or longer treatment regimens should
be evaluated in order to avoid relapses. In addition, the combined use of MF with other antil-
eishmanial drugs should be considered as an alternative for the chemotherapy of the disease.
Supporting Information
S1 Fig. Characterization of the transgenic line of L. braziliensis expressing luciferase. (A)
Growth curves for Lb-WT and Lb-LUC promastigote lines. Parasites were grown in M199 and
then counted using a Neubauer hemocytometer. Data is the mean and standard error from two
independent experiments. RLU, relative luminescence units. (B) Luciferase activity in logarith-
mic and stationary-phase Lb-LUC promastigotes. (C) Stability of luciferase expression in Lb-
LUC. Promastigotes were cultivated for 25 passages in the presence or absence of hygromycin
B and then tested for luminescence.
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S2 Fig. In vitro infectivity of Lb-LUC in BMDM.Macrophages were infected with stationary
phase promastigotes for 3 hours at 33°C. Non-internalized parasites were removed by washing
with warmed PBS. (A) and (B): Representative images of macrophages infected with Lb-WT
(A) and Lb-LUC (B). (C) Percentage of infected macrophages after 24 or 48 hours. Cells were
infected with a ratio of 20 parasites per macrophage. The percentage of infection was deter-
mined by counting 100 cells in triplicates. (D) Number of amastigotes per infected macrophage
after 24 or 48 hours. (E) Macrophage infection evaluated through luminescence. Relative lumi-
nescence units (RLU) were determined for macrophages after infection with different ratios of
parasites per macrophage (25:1, 30:1 and 35:1). The average and standard deviation of three
independent experiments in triplicates is shown for both experiments. Anova with Tukey’s
post test: () P< 0.05; () P<0.01; () P<0.001.
(DOCX)
S3 Fig. In vivo efficacy of miltefosine in L. braziliensis-inoculated BALB/c mice. 106 Lb-WT
stationary-phase promastigotes were injected in the mice left hind footpad. Treatment with 5
or 15 mg/kg/day of miltefosine was given for 15 consecutive days (from 4th to 6th week post-
inoculation). Average of lesion size was measured weekly (five animals per group) in untreated
and treated animals The horizontal black bar indicates MF treatment and the arrows indicate
the time points when parasites were recovered from BALB/c mice treated with 5 or 15 mg/kg/
day (19th and 23th week respectively).
(DOCX)
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